Researchers have developed IBIO-600, an experimental antibody drug that blocks two muscle-limiting proteins and successfully preserved lean muscle mass in obese mice receiving weight-loss medication, with a 52-day duration in monkeys’ bodies. According to Gram Research analysis, this preclinical research suggests the drug could help people maintain muscle strength while losing weight with GLP-1 medications, though human testing has not yet begun.
Scientists have created a new experimental drug called IBIO-600 that could help people preserve muscle mass while losing weight with GLP-1 medications like Ozempic and Wegovy. The drug works by blocking two proteins—myostatin and GDF11—that naturally limit muscle growth. In early testing on mice and monkeys, the drug successfully maintained lean muscle while weight loss occurred. According to Gram Research analysis, this represents a significant advancement because current weight-loss drugs can sometimes cause unwanted muscle loss alongside fat loss. The findings suggest IBIO-600 could improve the overall quality of weight loss by keeping people stronger and healthier during their weight-loss journey.
Key Statistics
A preclinical study published in Scientific Reports in 2026 found that IBIO-600, a dual-targeting antibody, preserved lean muscle mass in obese mice treated with GLP-1 weight-loss medication compared to medication alone.
In aged obese monkeys, a single injection of IBIO-600 demonstrated an elimination half-life of approximately 52 days, suggesting the drug could remain active in the body for extended periods between doses.
Laboratory research showed that GDF11 more potently affects human muscle and fat cell biology than myostatin, supporting the development of antibodies that target both proteins simultaneously.
The Quick Take
- What they studied: Whether a new experimental antibody drug (IBIO-600) could preserve muscle mass in people taking weight-loss medications, and how long the drug stays active in the body.
- Who participated: Laboratory studies using human muscle cells, obese mice receiving weight-loss medication, and obese monkeys to test safety and effectiveness.
- Key finding: IBIO-600 successfully preserved lean muscle mass in mice on weight-loss drugs and remained active in monkeys’ bodies for approximately 52 days after a single dose.
- What it means for you: If approved for human use, this drug could help people maintain muscle strength and tone while losing weight with GLP-1 medications, potentially improving overall health outcomes. However, this is still early-stage research and human trials have not yet begun.
The Research Details
Researchers developed IBIO-600, a long-acting antibody designed to block two muscle-limiting proteins called myostatin and GDF11. They tested it in three ways: first in human muscle cells grown in the laboratory to see if it could restore normal muscle growth, second in obese mice receiving GLP-1 weight-loss medication to see if it preserved muscle during weight loss, and third in obese monkeys to measure how long the drug stays active in the body and whether it improved body composition.
The laboratory studies examined how myostatin and GDF11 affect muscle and fat cells, revealing that GDF11 has a stronger effect on human cells than previously thought. The animal studies measured muscle preservation, body composition changes, and drug persistence in the bloodstream over time.
This research approach is important because it bridges the gap between basic science and real-world application. Testing in human cells first ensures the drug works as intended at the cellular level. Testing in mice provides quick feedback on effectiveness during weight loss. Testing in monkeys—which are biologically more similar to humans than mice—provides crucial information about how long the drug lasts in the body and whether it actually works in a living system closer to humans.
This is preclinical research, meaning it has not yet been tested in humans. The study was published in Scientific Reports, a peer-reviewed journal, which means other scientists reviewed the work. The researchers used multiple model systems (cells, mice, and monkeys) to strengthen their findings. However, preclinical results do not always translate to human effectiveness, and safety in humans remains unknown.
What the Results Show
In laboratory studies with human muscle cells, IBIO-600 successfully reversed the muscle-growth-blocking effects of myostatin and GDF11, allowing muscle cells to grow and develop normally. This demonstrates the drug works at the cellular level as intended.
In obese mice receiving GLP-1 weight-loss medication, IBIO-600 preserved lean muscle mass compared to mice receiving the weight-loss drug alone. This is significant because it shows the antibody can prevent the muscle loss that sometimes occurs during weight loss.
In obese monkeys given a single injection of IBIO-600, the drug remained active in the bloodstream for approximately 52 days. This long duration is important because it means patients would not need frequent injections—potentially only a few times per year. The monkeys also showed sustained improvements in body composition, meaning better muscle-to-fat ratios.
The research revealed that GDF11 has a more powerful effect on human muscle and fat cells than myostatin, suggesting that blocking both proteins may be more effective than blocking myostatin alone. This finding influenced the drug’s design to target both proteins simultaneously. The drug’s long half-life (52 days in monkeys) suggests it could be administered infrequently, improving patient convenience and compliance.
Previous research showed that blocking myostatin alone could preserve some muscle during weight loss. This study advances that knowledge by showing that a dual-targeting antibody (blocking both myostatin and GDF11) may be more effective. The long-acting design represents an improvement over shorter-acting treatments, as it requires fewer injections. The findings align with growing interest in improving weight-loss quality by preserving muscle alongside fat loss.
This is preclinical research conducted in cells and animals, not humans. Results in mice and monkeys do not guarantee the drug will work the same way in people. The study did not test the drug’s safety profile in humans or identify potential side effects. Long-term effects in living organisms were not extensively studied. The research does not include information about optimal dosing for humans or how the drug would interact with other medications. Human clinical trials would be necessary before this drug could be prescribed.
The Bottom Line
This research is too early-stage to make clinical recommendations. IBIO-600 is not yet available for human use and has not undergone human safety testing. People currently taking GLP-1 medications should not expect this drug to be available soon. If concerned about muscle loss during weight loss, current evidence-based approaches include resistance exercise and adequate protein intake, which are proven to preserve muscle mass.
This research is most relevant to people taking or considering GLP-1 weight-loss medications who are concerned about muscle loss. It may also interest people with age-related muscle loss (sarcopenia) or muscle-wasting conditions, though the current research focuses on weight loss. Healthcare providers and pharmaceutical companies developing obesity treatments should monitor this development. People should not seek out experimental versions of this drug, as it is not yet approved for any use.
IBIO-600 is in preclinical development. If development proceeds on a typical timeline, human safety trials (Phase 1) could begin within 1-3 years. Efficacy trials (Phase 2-3) would take several additional years. If successful, regulatory approval could occur 5-10 years from now. This is a realistic but uncertain timeline, as many promising preclinical drugs do not successfully transition to human use.
Frequently Asked Questions
Can I get IBIO-600 to prevent muscle loss while taking Ozempic or Wegovy?
IBIO-600 is not yet available for human use. It is in preclinical development and has only been tested in cells and animals. Human clinical trials have not begun. Current evidence-based strategies to preserve muscle during GLP-1 use include resistance exercise and adequate protein intake.
How long does IBIO-600 stay in your body?
In monkeys, IBIO-600 remained active for approximately 52 days after a single injection. This long duration suggests infrequent dosing would be possible if approved for humans, but human pharmacokinetics may differ from animal studies.
What is myostatin and why does blocking it help preserve muscle?
Myostatin is a natural protein that limits muscle growth. Blocking it allows muscle cells to grow and develop more freely. During weight loss, blocking myostatin helps preserve existing muscle mass rather than losing it alongside fat.
When will IBIO-600 be available as a treatment?
IBIO-600 is years away from potential human use. Preclinical research must be followed by human safety trials, then efficacy trials. If development proceeds successfully, approval could realistically occur 5-10 years from now, though this timeline is uncertain.
Is muscle loss a real problem when taking weight-loss medications?
Yes, GLP-1 medications can cause some muscle loss alongside fat loss. Research shows that resistance training and adequate protein intake help preserve muscle during weight loss. Maintaining muscle is important for strength, metabolism, and overall health quality.
Want to Apply This Research?
- Users taking GLP-1 medications could track weekly body composition metrics (muscle mass percentage, lean mass in pounds) using bioelectrical impedance scales or DEXA scans, alongside weight and waist circumference, to monitor whether they’re losing fat while preserving muscle.
- Users could set a goal to combine GLP-1 medication use with resistance training 2-3 times weekly and track protein intake (targeting 0.7-1.0 grams per pound of body weight), as these evidence-based strategies currently preserve muscle during weight loss.
- Establish a monthly check-in to compare body composition changes rather than weight alone. Track metrics like strength improvements (weight lifted in key exercises), energy levels, and how clothes fit—all indicators of muscle preservation. This approach helps users understand that weight loss quality matters as much as weight loss quantity.
This article describes preclinical research that has not been tested in humans. IBIO-600 is an experimental drug and is not approved for any use in people. The findings in animals do not guarantee similar results in humans. Anyone taking GLP-1 medications should consult their healthcare provider about strategies to preserve muscle mass, such as resistance exercise and adequate protein intake. Do not seek experimental versions of this drug or any unapproved treatments. This article is for educational purposes only and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.